Introduction
============

Adult growth hormone deficiency (AGHD) is a debilitating condition that occurs due to insufficient secretion of GH from the pituitary gland. AGHD is caused by hereditary defects of GH synthesis and secretion or resulted from tumor, head injury, and head radiation or pituitary surgery. Besides metabolic disorders, osteoporosis, sarcopenia and decreased quality of life, impaired cognitive function is one of the important characteristics of AGHD ([@B27]; [@B35]). AGHD can be divided into childhood-onset and adulthood-onset, according to the age of onset. Most cases of isolated growth hormone deficiency (GHD) in childhood are idiopathic and transient, while in patients with multiple pituitary hormone deficiency (MPHD), GHD generally persists into adulthood ([@B8]; [@B41]).

Brain morphology and function could be influenced during early stages of development in the uterus and can dynamically change during adulthood ([@B10]). GH is a peptide synthesized by the anterior pituitary that stimulates insulin-like growth factor-1 (IGF-1) secretion from the liver. GH receptor and IGF1 receptor have been localized in brain regions important in cognitive functioning, including the hippocampus, amygdala and parahippocampal areas ([@B1]). The GH/IGF1-axis plays an essential role during early brain development and persists in several brain regions with continuous renewal and remodeling during adulthood ([@B39]). In neural stem cells, IGF-1 is a controlling switch for long-term proliferation ([@B33]). A higher serum IGF-1 level is associated with better working memory and mental processing speed in healthy subjects ([@B3]). Morphologically, higher serum IGF-1 levels are associated with significantly increased cerebral blood flow in the left dorsolateral prefrontal cortex and left premotor cortex ([@B7]).

Despite the role of the GH/IGF-1 axis in normal brain development and function, the effects of GHD on brain structure are not fully understood thus far. It was reported that reduced thalamic and globus pallidum volumes were related to deficits in cognitive function and motor performance in children with isolated GHD ([@B37]). In patients with MPHD, GHD is usually permanent and recombinant human GH (rhGH) replacement is usually stopped after completion of linear growth. Higher incidence of mental disorders and increased prevalence of cognitive dysfunction were reported in hypopituitary women with GH deficiency ([@B11]). There were also several studies to evaluate the effects of GH replacement therapy in cognitive function improvement in AGHD patients. But interpretation of data is complicated by participants selection as well as neuropsychological tests used in these studies ([@B36]). Morphological variations in the brains of patients with childhood-onset AGHD after cessation of rhGH treatment have received little research attention to date.

Recently, voxel-based statistical analysis based on an ^18^F-FDG PET study found that adult patients with GHD due to traumatic brain injury had decreased cerebral glucose metabolism in cortical areas involved in intellectual function, executive function and working memory ([@B30]). No direct assessment of cortical thickness of AGHD patients has been reported so far. Cortical thickness provides direct and reliable information about the density, size and arrangement of cortical cells, thus yielding insights into the regional integrity of the cerebral cortex. One of the main challenges in evaluation of brain structure variations in patients with AGHD is the lack of homogeneity in etiology, course of disease and variation of hormone replacement therapy. In this cross-sectional study, cortical thickness of adult males with childhood-onset AGHD due to pituitary hypoplasia or pituitary stalk interruption was compared to age- and gender-matched healthy controls. The effects of disease status and hormone levels on cortical thickness were also evaluated.

Subjects and Methods
====================

Participants
------------

In this cross-sectional study, a total of 17 consecutive male patients with childhood-onset AGHD were enrolled from January 2011 to March 2013 in Peking Union Medical College Hospital ([@B38]). Inclusion criteria included: (1) all patients fulfilled the diagnosis criteria of AGHD according to the clinical guideline of the American Endocrine Society ([@B27]). Twelve patients underwent insulin tolerance test and peak value of GH was lower than 3 ng/ml. The diagnosis was confirmed in the other five patients with IGF-1 levels below the age-adjusted normal range and deficiencies in three or more pituitary axes at the same time., (2) linear growth was finished and bone age ≥18 years, (3) rhGH had been stopped at least one year after final height, (4) prednisone, [L]{.smallcaps}-thyroxine and testosterone replacement therapy were sustained as needed at least one year before enrollment, and (5) right handedness and with no contraindication to MRI. A total of 17 healthy age-matched male subjects were enrolled as controls. All controls were right-handed and education-matched. Medical history of major neurological or psychiatric disorders was documented in neither the AGHD group nor the control group. The study protocol was approved by the Ethics Committees of Peking Union Medical College Hospital. Written informed consent was obtained from all subjects and all data were de-identified before analysis.

Clinical Assessment
-------------------

Main demographic data were obtained from medical charts. Weight and height were measured in the early morning. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Questionnaires about education levels were assessed. Blood samples were also obtained in early morning. Serum levels of IGF1, free thyroxine (FT4) free triiodothyronine (FT3), thyrotropin (TSH), total testosterone and fasting blood glucose were tested in the department of the clinical laboratory using standard protocols ([@B43]).

MRI Image Acquisition
---------------------

Imaging was performed on a 3 T MR scanner (General Electric Medical Systems, GE sign VH/I Excite I 3.0 T). Lying in supine position, participants fixed their heads using foam padding to avoid head movement. A scout for anterior commissure-posterior alignment was done first, then sagittal three-dimensional (3D) volumetric T1-weighted magnetization-prepared rapid acquisition gradient echo (MPRAGE) images were obtained (128 sagittal slices, repetition time (TR) = 2530 ms, echo time (TE) = 3.39 ms, inversion time (TI) = 1100 ms, slice thickness = 1.33 mm, field of view (FOV) = 256 × 256 mm^2^, voxel size = 1.33 × 1.00 × 1.00 mm^3^).

Image Processing
----------------

Cortical thickness was extracted from the structural MR T1 images by using a routine pipeline of the CIVET software (version 1.1.9; Montreal Neurological Institute at McGill University, Canada). A flowchart for cortical thickness assessment was described previously ([@B25]). In brief, the original images were linear registered to stereotaxic space using the average NMI-ICBM152 model, for obtaining better segmentation following ([@B15]). Then the non-uniformity artifacts of images were corrected by the Non-parametric Non-uniform intensity Normalization (N3) algorithm ([@B32]), which was shown to be accurate and robust ([@B32]). By using an advanced neural classifier, the registered and corrected images were then segmented into white matter (WM), grey matter (GM), cerebrospinal fluid (CSF) and background ([@B44]; [@B19]). The inner and outer GM surfaces were extracted from each hemisphere by using the constrained Laplacian-based automated segmentation with proximities (CLASP) algorithm ([@B26]; [@B20]). Specifically, the inner surface was reconstructed by deforming a spherical polygon model to the WM/GM boundary with a total of 81,924 vertices (40,962 of each hemisphere). The outer surface was then initiated from the inner surface and was expanded to the GM/CSF fluid boundary along the Laplacian field generated from a skeletonized CSF fraction image ([@B12]; [@B13]). Cortical thickness was defined as the Euclidean distance between linked vertices on the inner and outer surfaces ([@B23]). For each subject, we visually evaluated the results of segmentation and reconstruction using the recommended method, and ensured that no error and failure was appeared. Finally, a 20-mm 2-D smoothing was applied on cortical thickness map for less noise and better sensitivity in statistics analysis.

Statistical Analysis
--------------------

Numerical data are expressed as the mean ± standard deviation, and *t*-tests were used to compare data between two groups. A general linear model (GLM) was used for thickness modeling at each surface vertex as a linear combination of effects related to variables of interests and effects of potential confounds (years of education, age and BMI). The main effect of groups and the interaction between groups and hormone levels were tested. As described previously, a random field theory (RFT)-based method was used at the cluster level for all cortical analysis in order to correct for multiple comparisons. Cortical clusters with an FWE-corrected *p* \< 0.05 were considered significant. After the interaction analyses, we performed the *post hoc* tests for the significant clusters. We used the Pearson's correlations (r) to quantify the relationship between hormone levels and averaged cortical thickness of clusters within each group. All statistical analyses were carried out using the SurfStat toolbox^[1](#footnote1){ref-type="fn"}^ in MATLAB ([@B42]).

Results
=======

Demographic, Clinical and Biochemical Characteristics
-----------------------------------------------------

Demographic and clinical characteristics are listed in [Table 1](#T1){ref-type="table"}. Nine of AGHD patients (9/17) were born with breech or foot presentation. MRI revealed pituitary hypoplasia or pituitary stalk interruption in all these patients. All patients had MPHD. All patients had MPHD and sustained glucocorticoid and levothyroxine replacement since childhood. Testosterone replacement was started at 18 years old and after completion of linear growth in all patients. AGHD group had received 32.5 ± 3.5 months of replacement therapy with rhGH and stopped after completion of linear growth.

###### 

General baseline data and distribution of all subjects.

                                   **AGHD group (*n* = 17)**   **Controls (*n* = 17)**   ***p***
  -------------------------------- --------------------------- ------------------------- ---------
  Age (years)                      25.0 ± 4.6                  24.0 ± 3.9                0.87
  Height (cm)                      163.5 ± 6.7                 173.0 ± 5.1               \<0.001
  Weight (kg)                      62.1 ± 10.3                 71.5 ± 8.2                0.006
  BMI (kg/m^2^)                    23.2 ± 3.3                  23.9 ± 2.8                0.47
  Education duration (years)       11.4 ± 3.2                  12.1 ± 3.0                0.55
  Fasting blood glucose (mmol/L)   5.0 ± 0.5                   5.1 ± 0.4                 0.65
  IGF-1 (ng/ml)                    49.1 ± 26.1                 234.0 ± 88.1              \<0.001
  IGF-1 SDS                        −5.04 ± 1.60                −0.35 ± 1.17              \<0.001
  FT3 (pg/ml)                      2.8 ± 0.7                   3.7 ± 0.3                 \<0.001
  FT4 (ng/dl)                      0.9 ± 0.4                   1.0 ± 0.2                 \<0.001
  TSH (μIU/ml)                     1.4 ± 1.2                   1.9 ± 0.8                 0.18
  Testosterone (ng/dl)             462.9 ± 161.3               478.0 ± 121.4             0.75

There was no difference in chronological age (25.0 ± 3.6 vs. 24.0 ± 3.9 years, *p* = 0.87) or school-education years between AGHD group and the control group. The AGHD group had a 9.5 cm lag in final height (163.5 ± 6.7 vs. 173.0 ± 5.1 cm, *p* \< 0.001) and lower body weight (62.1 ± 10.3 vs. 71.5 ± 8.2 kg, *p* = 0.006) compared with the control group. BMI was similar between the two groups. AGHD group presented with a significant decrease in IGF1 levels at the time of the study (49.1 ± 26.1 vs. 234.0 ± 88.1 ng/ml, *p* \< 0.001). With monthly intramuscular injections of testosterone undecanoate, serum levels of the AGHD group were similar to that of the control group (*p* = 0.75). With daily replacement with levothyroxine, serum levels of FT4 and FT3 in the AGHD group were in the lower quartile of the normal range, but were significantly lower than controls (*p* \< 0.001).

Alterations of Brain Volumes
----------------------------

As shown in [Table 2](#T2){ref-type="table"}, there was no difference in whole brain volume (*p* = 0.20) or gray matter volume (*p* = 0.08) between the AGHD and control groups.

###### 

Comparison of whole brain volume and gray matter between study groups.

                               **AGHD group (*n* = 17)**   **Control group (*n* = 17)**   ***p***
  ---------------------------- --------------------------- ------------------------------ ---------
  Whole brain volume (mm^3^)   1526.54 ± 134.38            1464.61 ± 141.50               0.20
  Gray matter volume (mm^3^)   697.69 ± 59.09              661.08 ± 59.09                 0.08

Alteration of Cortical Thickness in Different Lobes and Regions
---------------------------------------------------------------

Compared with the control group, the AGHD group showed decreased cortical thickness in the parahippocampal gyrus (Brodmann's area 27), posterior cingulate gyrus (Brodmann's area 29, 30) and occipital visual syncortex Brodmann's area 17, 18, 19)([Figure 1A](#F1){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). While in the partial area of the frontal lobe (Brodmann's area 9, 10, 11, 47), parietal lobe (Brodmann's area 7,39) and occipital visual syncortex (Brodmann's area 17, 18, 19), the AGHD group showed increased cortical thickness ([Figure 1B](#F1){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). The significant clusters are different and exclusive, although some of them belong to same Brodmann's region like Brodmann's area 17, 18, 19. There was no overlap between these parts.

![Alterations in cortical thickness in young male patients with childhood-onset adult growth hormone deficiency. Clusters with FWE-corrected *p* \< 0.05 are shown, and the color corresponds to the *p*-value. Areas in blue represent decreased cortical thickness in AGHD compared to controls, and yellow area represent increased thickness. **(A)** Clusters of significantly reduced cortical thickness in the AGHD group compared to controls. **(B)** Clusters of significantly increased cortical thickness in the AGHD group compared to controls.](fnins-13-01134-g001){#F1}

###### 

Regional variation of cerebral cortex thickness in AGHD patients compared with normal control.

  **Cortex thickness: AGHD vs. control**   **Brodmann's areas**     **Cluster size**   **Peak *x***   **Peak *y***   **Peak *z***   **Peak *T*-value**
  ---------------------------------------- ------------------------ ------------------ -------------- -------------- -------------- --------------------
  AGHD \> control                          7, 10, 11, 19, 39        1225               −37            −57            44             4.63
                                           17, 18, 19               731                45             −79            −18            5.13
                                           9                        191                −27            14             49             3.8
                                           47                       157                −46            44             −16            4.59
  AGHD \< control                          17, 18, 19, 27, 29, 30   2720               21             −55            1              7.23
                                           23                       115                −21            −69            5              4.89

Interaction Analysis
--------------------

The associations between cortical thickness and serum IGF-1 levels were not significantly different between the two groups after adjusting for serum levels of FT3. Meanwhile associations between groups and serum FT3 levels and the effects on cortical thickness was found in our data (*F* = 16.55, *df* = 1, 29, *p* \< 0.001). Cortical thickness of the posterior cingulum gyrus was prominently only associated with serum levels of FT3 in control group after adjusting for IGF-1 levels (AGHD group, *r* = −0.28, *p* = 0.27; control group, *r* = −0.66, *p* = 0.004; [Figure 2](#F2){ref-type="fig"}).

![Effects of interaction between groups and serum FT3 levels on cortical thickness. Red points, controls; blue points, AGHD patients.](fnins-13-01134-g002){#F2}

Discussion
==========

This cross-sectional study focused on cortical thickness alterations of young male patients with childhood-onset AGHD after cessation of rhGH replacement therapy. Our results showed that: (1) Compared to age-, gender- and education-matched controls, the AGHD group had significantly decreased IGF1 levels. With routine replacement of levothyroxine, serum FT4 and FT3 levels in the AGHD group were in the lower quartile of the normal range, but were significantly lower than for the controls. (2) Although there was no difference in whole brain volume or gray matter volume between the two groups, there was a decreased cortical thickness in the parahippocampal gyrus, posterior cingulate gyrus and occipital visual syncortex in the AGHD group, as well as an increased cortical thickness in the partial area of the frontal lobe, parietal lobe and occipital visual syncortex. (3) Cortical thickness of the posterior cingulum gyrus was prominently associated with serum levels of FT3 in the control group after adjusting of IGF-1 levels, and the relationship was not observed in AGHD group.

The GH/IGF-1 axis plays an important role in brain development and maintenance of cognitive function ([@B5]). The GH receptor is prominently expressed in the hypothalamus, hippocampus, putamen and choroid plexus ([@B21]). Meanwhile, IGF-1 receptors are expressed in cerebellum, prefrontal cortex, caudate nucleus, amygdala, hippocampal and parahippocampal area ([@B9]). During adolescence, gene expression in hippocampal area was reported to be regulated by IGF1 ([@B40]). In mice, the GH/IGF-1 axis plays a specific role in corticospinal tract development, and corticospinal axon growth will be impaired as the result of an interruption to IGF-1 signaling ([@B29]). However, how the disease process impacts the structural integrity of the brain in humans still needs further investigation. In children with isolated GHD, it was reported that there were decreased volumes in the right hippocampus, right pallidum and left thalamus, compared to controls ([@B37]). However, no previous studies have evaluated the structural characteristics in patients with MPHD after cessation of rhGH replacement therapy so far. In our study, all subjects had childhood-onset MPDH and stopped rhGH replacement therapy after completion of linear growth. Cortical thickness in the parahippocampal gyrus, posterior cingulate gyrus and occipital visual syncortex decreased, while cortical thickness in partial area of the frontal lobe, parietal lobe, occipital visual syncortex and angular gyrus increased in our AGHD subjects. The variations of cortical thickness in the cingulate cortex and frontal lobe are consistent with previous reports from young patients with GH receptor deficiency ([@B28]), since IGF-1 signaling is supposed to play an important role in brain regeneration in these areas. However, variations of cortical thickness in the occipital visual syncortex, angular gyrus and parahippocampal gyrus have not been described in AGHD patients before, and functional implications need to be further investigated.

Patients with AGHD were reported to have impaired cognitive function (memory and attention) in several neuropsychological studies, and there are several reports evaluating GH replacement therapy in cognitive function improvement in AGHD patients ([@B17]). Several structures are known to play important roles in cognitive function, including memory and learning, and distribution of IGF-1 receptors reportedly interact with the hippocampal cholinergic system and are involved in cognitive development ([@B6]; [@B9]). In the elderly, higher concentrations of serum IGF-1 levels were associated with better performance on cognitive function tests, which suggested that the GH/IGF-1 axis may affect cognitive function throughout life ([@B2]). In our AGHD subjects, decreased cortical thickness was found in parahippocampal gyrus, posterior cingulate gyrus and occipital visual syncortex. The parahippocampal gyrus surrounds the hippocampus and is part of the limbic system and plays an important role in memory encoding and retrieval. It was reported that parahippocampal cortical thickness was reduced in people at ultra-high risk of psychosis ([@B34]). The posterior cingulate cortex is made up of an area around the midline of the brain, communicates with various brain networks simultaneously and is involved in diverse functions ([@B22]). Reduced cortical thickness of the posterior cingulate was reported in patients with improved migraines, and thus, it was hypothesized to be related with chronic pain development ([@B4]). The occipital visual syncortex is located in the occipital lobe and is involved in visual information processing. Childhood onset of blindness significantly affects the cortical thickness of the primary visual cortex ([@B24]). Cortical thickness changes of the above three areas have not been evaluated in GHD thus far. There are also some regions with increased cortical thickness, some of which play different roles in cognition, semantic processing and sensory afferents. The significance of these alterations, and whether rhGH replacement has any effect on them, needs further assessments.

At the same time, the associations between cortical thickness and serum IGF-1 levels were not significantly different between two groups after adjusting for serum levels of FT3. Meanwhile an association between groups and serum FT3 levels and the effects on cortical thickness was found in our data. Cortical thickness of posterior cingulum gyrus was prominently associated with serum levels of FT3 only in the control group after adjusting for IGF-1 levels. These results may suggest that the effects of the thyroid hormone on cortical thickness in AGHD patients have been lessened in the presence of GHD. The thyroid hormone plays an essential role in early stages of brain development ([@B16]), and structures including the hippocampus, striatum and cortex are reported to be abnormal in rats ([@B31]), mice ([@B18]) and children ([@B14]) with hypothyroidism. Children with congenital hypothyroidism showed cortical thinning or thickening in a few areas ([@B14]), which are different from all the changed areas found in our study. The interaction between the GH and thyroid hormone and its effects on the maintenance of cortical thickness in different regions of the brain is not clear to date, and animal models may provide further information for this interplay.

There are several limitations in this study. The first and most important one is the limited number of subjects, however, there was relatively good homogeneity in the etiology, age of onset, duration of rhGH treatment and time course since cessation of rhGH treatment, which provided a general uniform background for morphology evaluation. Stable rules in interaction analysis will be warranted with more samples in further investigation. Another limitation is the cross-sectional nature of this study, which does not provide a cause-effect rationale for GHD and changes in cortical thickness. The third limitation is cognitive tests had not been assessed in AGHD patients since alterations of cortical thickness may be related to changed cognitive function. Further prospective studies are needed to shed new lights on the effects of GH replacement therapy on brain structure changes and cognitive function improvement in AGHD patients.

In summary, our findings indicate that young male patients with childhood-onset AGHD who are no longer receiving GH replacement have alterations in cortical thickness in different brain lobes/regions. It will be important to expand on these results in a larger sample size, ideally incorporating not only structural, but also functional brain measures.
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